42:I[58016,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"ProcessEpisodeButton"] 44:I[185,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SendEmailButton"] 45:I[45269,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SignupCTA"] 47:I[56939,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"EpisodeTranscript"] 3c:["$","div",null,{"className":"flex flex-col gap-2 text-sm text-muted-foreground","children":[["$","span",null,{"className":"inline-flex items-center gap-2 bg-secondary/50 px-3 py-1 rounded-full","children":[["$","svg",null,{"className":"w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"}]}],["$","time",null,{"dateTime":"2026-03-20T18:06:32.000Z","children":"Fri Mar 20 2026"}]]}],null]}] 43:T444,

touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY

Listen to leading experts discuss guideline-directed strategies for mutational analysis and monitoring response when treating patients with chronic-phase chronic myeloid leukaemia with approved tyrosine kinase inhibitors.

The experts

Dr Jorge Cortes, Georgia Cancer Center, Augusta, GA, USA
Dr Elias Jabbour, MD Anderson Cancer Center, Houston, TX, USA
Dr Vivian Oehler, Fred Hutch Cancer Center, Seattle, WA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc.

Jointly provided by Partners for Advancing Clinical Education and touchIME.

For further information, visit our websites:
www.touchHAEMATOLOGY.com
www.touchONCOLOGY.com

Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management